Papers
2
Total Citations
17
H-Index
2
About
Amy Bowman is a pioneering researcher in the automation of biochemical assays and analytical method development for next-generation vaccines. Her work focuses on integrating open-source, cost-effective robotic liquid handlers into high-throughput screening workflows, significantly advancing the efficiency of drug discovery and development. In 2024, her landmark paper on automating biochemical assays with an inexpensive robotic system garnered 11 citations, highlighting its practical impact on pharmaceutical and vaccines analytical research. Bowman’s major contributions extend to the critical area of mRNA vaccine safety, where she developed and applied an automated sandwich ELISA for quantitating residual double-stranded RNA (dsRNA)—a key impurity from in vitro transcription that can affect vaccine potency and patient safety. This work, cited 6 times, addresses a pressing need in the rapidly evolving mRNA vaccine landscape. Through her innovative integration of automation and analytical rigor, Bowman has established herself as a key figure in high-throughput analytics, enabling faster, more reliable assay development that directly supports the fight against global disease. Her achievements underscore a commitment to accessible, reproducible science that bridges engineering and biotechnology.
Research Focus
Key Achievements
Top Papers
- 1
- 2